One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Liver Diseases Therapeutics Market

[ 英語タイトル ] Liver Diseases Therapeutics Market- Growth, Trends, and Forecast (2020 - 2025)

Product Code : MDHC0084113
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Abbott Laboratories
- Astellas Pharma Inc.
- Bristol-Mayers Squibb
- Gilead Sciences
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Novartis AG
- Sanofi AG

[Report Description]

The liver diseases therapeutics market will show rapid growth due to the increasing prevalence of liver diseases, increase in consumption of alcohol and improper diet and increasing government initiatives of providing vaccines and growing awareness.

As per the study by Asrani et al., published in 2019, liver disease accounts for approximately 2 million deaths per year worldwide, out of which 1 million are due to complications of cirrhosis and 1 million is due to viral hepatitis and hepatocellular carcinoma. Cirrhosis is, therefore, the 11th most common cause of death globally and liver cancer is 16th leading cause of death; combined, they account for 3.5% of all deaths worldwide. Also, chronic liver disease mortality is expected to rise in the United States, driven largely by a spike in nonalcoholic fatty liver disease (NAFLD). Therefore increasing of the liver diseases has helped in driving the overall market.

Furthermore, with the increasing prevalence of liver diseases, government and other not-for-profit organizations are playing a crucial role in the rising awareness about liver diseases across the globe. Hence all these organizations are found promoting the awareness of the liver-related diseases and support for research and development for the prevention, treatment and cure of liver diseases.

Key Market Trends

Anti Viral Drugs Segment is Expected to Dominate the Market During the Forecast Period

- Antiviral drugs segment is found dominating the overall market due to the increasing consumption of alcohol and rising increasing prevalence of liver diseases and presence of strong pipeline drugs in this segment.
- On the other hand, chemotherapy drugs segment will also show promising growth rate over the forecast period and emerge as the most lucrative drug class in terms of returns on investment. The segment will chiefly benefit from the approval and commercialization of several anticipated pipeline drugs.

North America is Anticipated to Dominate the Liver Disease Therapeutics Market

- The market is found to be dominated by North America owing to the presence of research and academic institutes conducting clinical trial studies in the region. Changing lifestyle such as increasing consumption of alcohol, unhealthy diets have also increased the incidences of liver disease in the United States. Moreover, growing patient awareness levels and the introduction of new products targeting the unmet medical needs are expected to drive regional market growth over the forecast period.
- Asia Pacific is also expected to grow at the high CAGR due to the presence of unmet healthcare infrastructure needs and increasing the prevalence of liver diseases due to alcohol consumption.

Competitive Landscape

There are various companies that are found investing in their R&D to develop innovative and advanced treatment drugs for liver diseases. Therefore research and development of high efficient and less or no side effects pharmaceutical drugs would drive the market in the near future. The companies are also found focusing on organic growth strategies such as product launches, product approvals and others such as patents and events.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the Incidence of Liver Diseases
4.2.2 Increase in Consumption of Alcohol and Improper Diet
4.2.3 Rising Government Initiatives of Providing Vaccines and Growing Awareness
4.3 Market Restraints
4.3.1 Drugs Side-effects and Associated Risks
4.3.2 Stringent FDA Approvals and Other Government Regulations
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Treatment Type
5.1.1 Anti Viral Drugs
5.1.2 Targeted Therapy
5.1.3 Immunosuppressant Drugs
5.1.4 Chemotherapy Drugs
5.1.5 Immunoglobulin
5.1.6 Vaccines
5.1.7 Others
5.2 By End Users
5.2.1 Hospitals
5.2.2 Ambulatory Surgery Centers
5.2.3 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Astellas Pharma Inc.
6.1.3 Bristol-Mayers Squibb
6.1.4 Gilead Sciences
6.1.5 GlaxoSmithKline plc
6.1.6 F. Hoffmann-La Roche Ltd.
6.1.7 Merck & Co., Inc.
6.1.8 Novartis AG
6.1.9 Sanofi AG




Recommended reports